Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 7/20 | 0.58 |
| ▸ | HPRT1 | P00492 | 7/20 | 0.58 |
| ▸ | BLM | P54132 | 2/20 | 0.53 |
| ▸ | TK1 | P04183 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | VCP | P55072 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | EDNRA | P25101 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | HBB | P68871 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1665922 | 1.00 | PNP (0.58) | PNPHPRT1BLMTK1MEN1 | |
| SCHEMBL10496683 | 0.94 | PNP (0.62) | PNPHPRT1BLMTK1USP2 | |
| SCHEMBL31273799 | 0.90 | HPRT1 (0.64) | PNPHPRT1BLMMEN1ALDH1A1 | |
| SCHEMBL9517549 | 0.87 | HPRT1 (0.62) | PNPHPRT1BLMTK1MEN1 | |
| Penciclovir SCHEMBL3495 | 0.85 | TK1 (0.70) | PNPHPRT1BLMTK1MEN1 | |
| SCHEMBL5930507 | 0.84 | PNP (0.52) | PNPHPRT1BLMTK1MEN1 | |
| Penciclovir SCHEMBL10414021 | 0.84 | TK1 (0.69) | PNPHPRT1BLMTK1MEN1 | |
| Penciclovir SCHEMBL7192792 | 0.84 | TK1 (0.69) | PNPHPRT1BLMTK1MEN1 | |
| Penciclovir SCHEMBL583037 | 0.84 | TK1 (0.69) | PNPHPRT1BLMTK1MEN1 | |
| SCHEMBL12800327 | 0.83 | TK1 (0.60) | PNPHPRT1BLMTK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130281470-A1 | Use of (R)-Penciclovir Triphosphate for the Manufacture of a Medicament for the Treatment of Viral Diseases | NOVARTIS AG (CH) | 2013-10-24 | — | — | US | disclosed |
| US-20110092458-A1 | Use of (R)-Penciclovir Triphosphate for the Manufacture of a Medicament for the Treatment of Viral Diseases | NOVARTIS PHARMACEUTICALS CORPORATION | 2011-04-21 | — | — | US | disclosed |
| US-7045525-B1 | Use of (R)-peniciclovir triphosphate for the manufacture of a medicament for the treatment of viral diseases | NOVARTIS AG (CH) | 2006-05-16 | — | — | US | disclosed |
| US-20060069108-A1 | Use of (R)-penciclovir triphosphate for the manufacture of a medicament for the treatment of viral diseases | NOVARTIS PHARMACEUTICALS CORPORATION | 2006-03-30 | — | — | US | disclosed |
| EP-0822817-B1 | USE OF (R)-PENCICLOVIR TRIPHOSPHATE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF VIRAL DISEASES | NOVARTIS INT PHARM LTD (BM) | 2003-07-23 | — | — | EP | disclosed |
| EP-0822817-A1 | USE OF (R)-PENCICLOVIR TRIPHOSPHATE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF VIRAL DISEASES | SMITHKLINE BEECHAM PLC (GB) | 1998-02-11 | — | — | EP | disclosed |
| WO-1996033720-A1 | USE OF (R)-PENCICLOVIR TRIPHOSPHATE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF VIRAL DISEASES | SMITHKLINE BEECHAM PLC (GB) | 1996-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092458-A1 | Use of (R)-Penciclovir Triphosphate for the Manufacture of a Medicament for the Treatment of Viral Diseases | TYMP, PNP, HPRT1 | PNP 2/4885HPRT1 3/4885BLM 1770/4885 |
| US-20130281470-A1 | Use of (R)-Penciclovir Triphosphate for the Manufacture of a Medicament for the Treatment of Viral Diseases | TYMP, PNP, HPRT1 | PNP 2/4885HPRT1 3/4885BLM 1770/4885 |
| US-20060069108-A1 | Use of (R)-penciclovir triphosphate for the manufacture of a medicament for the treatment of viral diseases | TYMP, PNP, HPRT1 | PNP 2/4885HPRT1 3/4885BLM 1770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.